ANPD001 for Parkinson's Disease

(ASPIRO Trial)

Recruiting at 8 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Aspen Neuroscience

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 0

9 Participants Needed

Trial Summary

What is the purpose of this trial?

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

Research Team

Edward D Wirth III, MD, PhD

Principal Investigator

Aspen Neuroscience

Eligibility Criteria

This trial is for individuals with Parkinson's Disease who are willing to have cells, previously collected from their own bodies, modified and injected back into their brain. The details of the eligibility criteria were not provided.

Inclusion Criteria

I am between 50 and 70 years old.

I was diagnosed with Parkinson's Disease over 4 years ago.

Met all eligibility requirements for inclusion in the trial-ready cohort in clinical study ANPD001-01

Exclusion Criteria

I cannot have an MRI or use gadolinium due to health reasons.

Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments

I've had brain surgery that makes me ineligible for ANPD001 treatment.

Treatment Details

Interventions

• ANPD001

Trial Overview The study is testing ANPD001, a treatment involving cells that mature into dopamine-producing neurons in the brain. Participants will receive these specialized cells derived from their own tissues.

Participant Groups

Group I: ANPD001 Experimental Treatment 2 Interventions

Who Is Running the Clinical Trial?

Aspen Neuroscience

Lead Sponsor

Trials

1

Recruited

9+

California Institute for Regenerative Medicine (CIRM)

Collaborator

Trials

70

Recruited

3,300+